Atabekoglu and colleagues compared AMH levels of 22 women undergoing TAH for uterine leiomyoma with healthy control group and reported decreased AMH after 4 months in TAH group (0.62 ± 0.9 ng/ml), which was 30% less than the control group (1.26 ± 1.78 ng/ml) (P < 0.001) [20]. The gene discussed is AMH; the disease is Uterine leiomyoma.